<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584257</url>
  </required_header>
  <id_info>
    <org_study_id>AS-MDI-301</org_study_id>
    <nct_id>NCT02584257</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma</brief_title>
  <official_title>Comparison of the Pharmacodynamic Profile of Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Bronchoprovocation in Adult Patients With Stable Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lupin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lupin Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test
      product to the reference product, using bronchoprovocation (methacholine challenge testing)
      in adult patients with stable mild asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, 5-Treatment, Randomized,
      Crossover Study to Demonstrate the Pharmacodynamic Bioequivalence of Test and Reference
      Metered Dose Inhalers containing Albuterol Sulfate using Bronchoprovocation in Adult Patients
      with Stable Mild Asthma
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provocative Concentration of Methacholine Causing 20 % Fall (PC20) in FEV1(Forced Expiratory Volume in 1 second)</measure>
    <time_frame>Following a single dose on day 1</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Mild Persistent Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose: 1 actuation each from 2 different placebo Reference inhalation aerosols and one actuation each from 2 different placebo Test inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>90 mcg of Reference product: 1 actuation each from the Reference product inhalation aerosol and the placebo Reference inhalation aerosol and 1 actuation each from 2 different placebo Test product inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mcg of Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180 mcg of Reference: 1 actuation each from 2 different Reference inhalation aerosols and 1 actuation each from 2 different placebo Test product inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg of Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mcg of Test product: 1 actuation each from the Test product inhalation aerosol and the placebo Test inhalation aerosol and 1 actuation each from 2 different placebo Reference inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mcg of Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 mcg of Test product: 1 actuation each from 2 different Test product inhalation aerosols and 1 actuation each from 2 different placebo Reference product inhalation aerosols</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>methacholine chloride</intervention_name>
    <arm_group_label>Placebo dose</arm_group_label>
    <arm_group_label>90 mcg Reference Product</arm_group_label>
    <arm_group_label>180 mcg of Reference product</arm_group_label>
    <arm_group_label>90 mcg of Test product</arm_group_label>
    <arm_group_label>180 mcg of Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo dose</intervention_name>
    <arm_group_label>Placebo dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg Reference Product</intervention_name>
    <arm_group_label>90 mcg Reference Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180 mcg of Reference product</intervention_name>
    <arm_group_label>180 mcg of Reference product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg of Test product</intervention_name>
    <arm_group_label>90 mcg of Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180 mcg of Test product</intervention_name>
    <arm_group_label>180 mcg of Test product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female subjects (18-65 years of age)

          -  Stable mild asthmatics based on National Asthma Education and Prevention Program
             (NAEPP) guidelines.

          -  Forced Expiratory Volume in 1 second ( FEV1) ≥ 80% of predicted. Airway responsiveness
             to methacholine demonstrated by a pre-albuterol dose (baseline) PC20 ≤ 8 mg/ml.

          -  Nonsmokers for at least 1 year prior to the study and a maximum smoking history of
             five pack-years (the equivalent of one pack per day for five years).

          -  Written informed consent.

        Exclusion Criteria:

          -  Conditions which could alter airway reactivity to methacholine (e.g., pneumonia, upper
             respiratory tract infection, lower respiratory tract, viral bronchitis and/or
             sinobronchitis) within six weeks preceding the screening visit.

          -  History of seasonal asthma exacerbations, in which case the patient should be studied
             outside of the relevant allergen season.

          -  History of cystic fibrosis, bronchiectasis or other respiratory diseases.

          -  History of cardiovascular, renal, neurologic, liver or endocrine dysfunction, or
             chronic condition that could put the safety of the patient at risk during the study or
             affect the efficacy and safety analyses during the study.

          -  Treatment in an emergency room, urgent care center, or hospitalization for acute
             asthmatic symptoms within the past 6 months or need for daily oral corticosteroids
             within past 3 months.

          -  Known intolerance or hypersensitivity to any component of the albuterol metered dose
             inhaler (MDI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational Research Center Site #110</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #114</name>
      <address>
        <city>Mission Viego</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #113</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #112</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #116</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #106</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #109</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #105</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #103</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #108</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #115</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #104</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #102</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #111</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #118</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #101</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Research Center Site #107</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

